Medical therapy versus revascularization: the atorvastatin versus revascularization treatment AVERT trial

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Previous studies indicated angioplasty improved symptoms over standard therapy in stable coronary artery disease (CAD).
• However, these studies did not incorporate aggressive cholesterol-lowering treatments.
• Angioplasty was associated with a slightly higher rate of death from myocardial infarction and other coronary events.

Purpose of the Study:

• To compare the efficacy of aggressive cholesterol-lowering therapy against percutaneous transluminal coronary angioplasty (PTCA).
• To evaluate treatment outcomes in low-risk, stable patients with coronary artery disease.

Main Methods:

• The Atorvastatin versus Revascularization Treatment (AVERT) trial was designed for this comparison.
• Patients with mild to moderate coronary disease were randomized to receive either atorvastatin or PTCA.

Main Results:

• Aggressive lipid-lowering therapy with atorvastatin significantly reduced low-density lipoprotein cholesterol levels.
• Atorvastatin treatment was associated with a 36% reduction in ischemic events.
• A significant delay in the time to the first ischemic event was observed in the atorvastatin group.

Conclusions:

• Aggressive lipid-lowering therapy is favored over percutaneous transluminal coronary angioplasty in stable patients with mild to moderate coronary artery disease.
• Atorvastatin therapy offers a superior strategy for reducing ischemic events in this patient population.
• The AVERT trial provides critical evidence for optimizing medical management in CAD.